BiotechTube

MK0782

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stomach Ulcer

Conditions

Stomach Ulcer, Duodenal Ulcer

Trial Timeline

Jun 1, 2004 → Aug 1, 2004

NCT ID
NCT00543868

About MK0782

MK0782 is a phase 2 stage product being developed by Merck for Stomach Ulcer. The current trial status is completed. This product is registered under clinical trial identifier NCT00543868. Target conditions include Stomach Ulcer, Duodenal Ulcer.

What happened to similar drugs?

1 of 8 similar drugs in Stomach Ulcer were approved

Approved (1) Terminated (1) Active (6)
✅E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
🔄epoetin alfaJohnson & JohnsonPhase 3
🔄Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
🔄Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
❌Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
🔄ECC + FOLFIRIRochePhase 3
🔄Capecitabine + OxaliplatinRochePhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00543465Phase 2Terminated
NCT00543868Phase 2Completed

Competing Products

20 competing products in Stomach Ulcer

See all competitors
ProductCompanyStageHype Score
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
43
ParietEisaiPre-clinical
26
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-FluorouracilEli LillyPhase 2
35
Ramucirumab + Capecitabine + Cisplatin + S-1 + OxaliplatinEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
39
epoetin alfaJohnson & JohnsonPhase 3
40
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
40
Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
40
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
32
AUY922 + BYL719NovartisPhase 1
29
ECC + FOLFIRIRochePhase 3
40
Capecitabine + OxaliplatinRochePhase 3
40
Atezolizumab + Capecitabine + Oxaliplatin + DocetaxelRochePhase 2
39
Atezolizumab + Tiragolumab + Oxaliplatin + CapecitabineRochePhase 2
27
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, CapecitabineAmgenPhase 2
35
AMG 337AmgenPhase 1/2
32
AMG 337AmgenPhase 2
27
Cisplatin + S-1 + SunitinibPfizerPhase 1
29
axitinib + capecitabine + cisplatinPfizerPhase 1
29